E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/6/2006 in the Prospect News Biotech Daily.

Flamel at neutral by Merrill

Flamel Technologies SA was kept at its neutral rating by Merrill Lynch analyst Hari Sambasivam. The company is to report fourth-quarter 2005 results on Tuesday. Merrill's estimates for the quarter include total revenues of $6.5 million, compared with $18.7 million for the same period last year, and a net loss of $8.2 million, or $0.35 per share, compared with net income of $6.5 million, or $0.28 per share, in the fourth quarter of 2004. The analyst's revised 2005 estimates are more in line with consensus, with a fourth-quarter loss per share of $0.35 from $0.29 and full-year loss per share of $1.25 from $1.20. Shares of the Venissieux, France, biopharmaceutical company were down $1.21, or 5.08%, at $22.59 on volume of 139,020 shares versus the three-month running average of 191,843 shares. (Nasdaq: FLML)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.